Serum Phospholipid Transfer Protein Mass as a Possible Protective Factor for Coronary Heart Diseases

Circulation Journal

Volumn 68, Issue 1, 2004, Pages 11-16

  Yatsuya, Hiroshi ^a   Tamakoshi, Koji ^a   Hattori, Hiroaki ^b   Otsuka, Rei ^a   Wada, Keiko ^a   Zhang, Huiming ^a   Mabuchi, Tomoko ^a   Ishikawa, Miyuki ^a   Murata, Chiyoe ^a   Yoshida, Tsutomu ^c   Kondo, Takaaki ^a   Toyoshima, Hideaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b BML   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Cohort study; Coronary heart disease; High density lipoprotein; Japan; Phospholipid transfer protein

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ETHNOLOGY; FOLLOW UP; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PREDICTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; STROKE; WORKPLACE;

ALCOHOL DRINKING; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; CARRIER PROTEINS; COHORT STUDIES; CORONARY DISEASE; HUMANS; JAPAN; LEISURE ACTIVITIES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OCCUPATIONAL HEALTH; PHOSPHOLIPID TRANSFER PROTEINS; RISK FACTORS;

EID: 0942266124     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.11     Document Type: Article

References (33)

1. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1096-1100.
2. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol 2002; 90: 139-143.
3. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: Protection against atherosclerosis. Atherosclerosis 2002; 161: 245-254.
4. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001; 42: 1586-1593.
5. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001; 155: 269-281.
6. Settasatian N, Duong M, Curtiss LK, Ehnholm C, Jauhiainen M, Huuskonen J, et al. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 2001; 276: 26898-26905.
7. van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20: 1082-1088.
8. Lie J, de Crom R, Jauhiainen M, van Gent T, van Haperen R, Scheek L, et al. Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of pre beta-high-density lipoproteins. Biochem J 2001; 360: 379-385.
9. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002; 13: 135-139.
10. Fournier N, Atger V, Cogny A, Vedie B, Giral P, Simon A, et al. Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: Consequences on the efflux capacity of serum in the Fu5AH system. Atherosclerosis 2001; 157: 315-323.
11. Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP. Low plasma lecithin: Cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: Role in altered high density lipoproteins. Atherosclerosis 2000; 153: 491-498.
12. Colhoun HM, Scheek LM, Rubens MB, Van Gent T, Underwood SR, Fuller JH, et al. Lipid transfer protein activities in type I diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 2001; 50: 652-659.
13. Riemens SC, van Tol A, Sluiter WJ, Dullaart RP. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: Blunted response to insulin in type 2 diabetic patients. Diabetes 1999; 48: 1631-1637.
14. Dullaart RP, van Tol A. Twenty four hour insulin infusion impairs the ability of plasma from healthy subjects and Type 2 diabetic patients to promote cellular cholesterol efflux. Atherosclerosis 2001; 157: 49-56.
15. Oka T, Kujiraoka T, Ito M, Nagano M, Ishihara M, Iwasaki T, et al. Measurement of human plasma phospholipid transfer protein by sandwich ELISA. Clin Chem 2000; 46: 1357-1364.
16. Huuskonen J, Ekstrom M, Tahvanainen E, Vainio A, Metso J, Pussinen P, et al. Quantification of human plasma phospholipid transfer protein (PLTP): Relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis 2000; 151: 451-461.
17. Oka T, Yamashita S, Kujiraoka T, Ito M, Nagano M, Sagehashi Y, et al. Distribution of human plasma PLTP mass and activity in hypo-and hyperalphalipoproteinemia. J Lipid Res 2002; 43: 1236-1243.
18. Tamakoshi K, Yatsuya H, Kondo T, Hirano T, Hori Y, Yoshida T, et al. The accuracy of long-term recall of past body weight in Japanese adult men. Int J Obes Relat Metab Disord 2003; 27: 247-252.
19. Yatsuya H, Tamakoshi K, Yoshida H, Hori Y, Zhang H, Ishikawa M, et al. Association between weight fluctuation and fasting insulin concentration in Japanese men. Int J Obes Relat Metab Disord 2003; 27: 478-483.
20. WHO MONICA Project, Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-512.
21. Karkkainen M, Oka T, Olkkonen VM, Metso J, Hattori H, Jauhiainen M, et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem 2002; 277: 15413-15418.
22. Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, et al. Distribution of phospholipid transfer protein in human plasma: Presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res 2000; 41: 1651-1657.
23. Yatsuya H, Ohwaki A, Tamakoshi K, Wakai K, Koide K, Otsuka R, et al. Reproducibility and validity of a simple checklist-type questionnaire for food intake and dietary behavior. J Epidemiol 2003; 13: 235-245.
24. World Health Organization. World health statistics annual 1995. Geneva: WHO, 1996.
25. Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 1857-1862.
26. van Haperen R, van Tol A, van Gent T, Scheek L, Visser P, van der Kamp A, et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 2002; 277: 48938-48943.
27. Kujiraoka T, Nanjee MN, Oka T, Ito M, Nagano M, Cooke CJ, et al. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb Vasc Biol 2003; 23: 1653-1659.
28. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103: 907-914.
29. Jiang XC, Qin S, Qiao C, Kawano K. Lin M. Skold A, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7: 847-852.
30. Hattori H, Kujiraoka T, Egashira T, Miyazaki A, Cooper JA, Miller NE. Coronary heart disease is strongly associated with plasma pre-beta-LPA-I concentration: Impact of high density lipoprotein remodeling by cholesteryl ester and phospholipid transfer proteins (abstract). Circulation 2000; 102(Suppl): 1391.
31. Jaari S, van Dijk KW, Olkkonen VM, van der Zee A, Metso J, Havekes L, et al. Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): Importance of PLTP in prebeta-HDL generation. Comp Biochem Physiol B Biochem Mol Biol 2001; 128: 781-782.
32. Tanabe N, Saito R, Sato T, Hayashi S, Toyoshima H, Seki N, et al. Event rates of acute myocardial infarction and coronary deaths in Niigata and Nagaoka cities in Japan. Circ J 2003; 67: 40-45.
33. Kita Y, Okayama A, Ueshima H, Wada M. Nozaki A, Choudhury SR, et al. Stroke incidence and case fatality in Shiga, Japan 1989-993. Int J Epidemiol 1999; 28: 1059-1065.